louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06888947: Influence of Collagen Cone on the Outcomes of Immediate Dental Implant Placement in Esthetic Zone
Official title: Influence of Collagen Cone on the Outcomes of Immediate Dental Implant Placement in Esthetic Zone
Study type: OBSERVATIONAL
Overall status: ENROLLING_BY_INVITATION
Conditions: Immediate Implant Placement
Evaluate Buccal Bone Plate Around Dental Implant
Keywords: immediate implant
collagen cone
Lead sponsor: Faculty of Dental Medicine for Girls
Sponsor class: OTHER_GOV
First posted: 2025-03-21
Enrollment: 16
Sex: ALL
Minimum age (years): 30
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patient with unrestorable tooth/teeth in esthetic zone seeking tooth/teeth replacement.

Brief summary: Influence of Collagen Cone on the Outcomes of Immediate Dental Implant Placement in Esthetic zone

Detailed description: The present study will be performed to assess effect of collagen cone for bone width and length around immediate implants in esthetics zone.

Eligibility criteria: Inclusion Criteria:

- 1-Patients were free from any systemic disease as evidenced by Burket's oral medicine health history questionnaire 2- Each patient required extraction of a non-restorable premolar or anterior tooth maxilla and requested implant restoration.

3-All patients should not have any known contraindication to oral surgery. 4-Male or female with age range 30 - 50 years.

Primary outcomes:
measure: 1- Clinical examination
timeFrame: 9 months
Secondary outcomes:
measure: CBCT
timeFrame: 9 months
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Hala Fathy
Study officials:
affiliation: Al-Azhar University
name: Abeer Gawish, professor
role: STUDY_DIRECTOR
affiliation: Al-Azhar University
name: lobna Abd-El Aziz, Lecturer
role: STUDY_DIRECTOR
References:
Clinical trial NCT05708547: Role of Mitophagy in Myeloid Cells During Coronary Atherosclerosis.
Official title: Role of Mitophagy in Myeloid Cells During Coronary Atherosclerosis.
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Coronary Atherosclerosis
Lead sponsor: Centre Hospitalier Universitaire Dijon
Sponsor class: OTHER
First posted: 2023-02-01
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Atheromatous coronary patients and non-coronary patients

Brief summary: Atherosclerosis (deposition of a plaque essentially composed of lipids on the artery walls) is a frequent condition and is a leading cause of death worldwide. In addition to the long-established risk factors such as age, hypertension, diabetes or sedentary lifestyle, it has been demonstrated that immune cells can participate in the genesis of atherosclerotic plaques through metabolic and mitochondrial reprogramming.

A non-invasive marker of this immune reprogramming has yet to be identified. Through the comparison of a group of atheromatous patients and a group of non-atheromatous patients, this study aims to evaluate this reprogramming phenomenon using a novel non-invasive method.

This monocentric interventional study will take place at the Dijon Bourgogne University Hospital and will include 50 patients divided into 2 groups: "atheromatous coronary patients" and "non-atheromatous patients". The duration of participation in this study is 1 month. This study is based on usually performed procedures. Only blood samples will be taken on a catheter usually used during any cardiac surgery in addition to the medical care that is provided during hospitalization.


Eligibility criteria: Inclusion Criteria:

- Person who provides oral consent

Group 1:

- Patient scheduled for cardiac bypass surgery (isolated procedure) with extracorporeal circulation

Group 2:

* Patient scheduled for valve ou ascending aorta surgery with extracorporeal circulation
* No coronary lesion
* No peripheral arterial disease (limbs, carotids, aortic aneurysm)

Exclusion Criteria:

* Person not affiliated with national health care system
* Medication that alters mitochondrial function (Chloroquine, hydroxychloroquine, rapamycin, carbamazepine, resveratrol, sildenafil)
* Person under a legal protection measure (curatorship, guardianship, tutorship)
* Pregnant, parturient or breastfeeding women
* Major unable to express consent
* Minor

Primary outcomes:
measure: Mitophagy level by flow cytometry
timeFrame: Before the introduction of extracorporeal circulation.
Secondary outcomes:
Other outcomes:
Locations:
city: Dijon
country: France
facility: Chu Dijon Bourgogne
Study officials:
References:
Clinical trial NCT01479647: A Study To Investigate The Effect Of Food On The Pharmacokinetics Of PH-797804
Official title: A Phase 1, Randomized, Open-Label, Single Dose, 2-Cohort Crossover Study To Determine The Effect Of Food On The Pharmacokinetics Of Orally Administered PH-797804 In Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Volunteers
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2011-11-24
Enrollment: 28
Sex: ALL
Minimum age (years): 21
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to investigate the effect of food on the time course of PH-797804 concentration in the blood following dosing by oral immediate release tablet formulation.


Eligibility criteria: Inclusion Criteria:

* Healthy male subjects and/or healthy female subjects of non-child bearing potential between the ages of 21 and 55 years (inclusive). Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurements, 12-lead ECG and clinical laboratory tests.
* Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \> 50 kg (110 lbs).

Exclusion Criteria:

* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
* A positive urine drug screen.
* History of regular alcohol consumption exceeding 21 drinks/week for males.

Primary outcomes:
measure: Pharmacokinetics: peak plasma concentration
timeFrame: 0,1,2,3,4,6,8,12,24,48,72,96,144,192,264,312 hours post-dose
measure: Pharmacokinetics: time to peak plasma concentration
timeFrame: 0,1,2,3,4,6,8,12,24,48,72,96,144,192,264,312 hours post-dose
measure: Pharmacokinetics: area under the plasma concentration-time curve
timeFrame: 0,1,2,3,4,6,8,12,24,48,72,96,144,192,264,312 hours post-dose
measure: Pharmacokinetics: terminal plasma half-life
timeFrame: 0,1,2,3,4,6,8,12,24,48,72,96,144,192,264,312 hours post-dose
Secondary outcomes:
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: Pfizer Investigational Site
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT01265147: Intensity-modulated Radiation Therapy Combined With Cisplatin or Nedaplatin Chemotherapy in Nasopharyngeal Carcinoma
Official title: Phase II Study to Evaluate Efficacy and Safety of Intensity-modulated Radiation Therapy Combined With Cisplatin or Nedaplatin Chemotherapy in Patients With Nasopharyngeal Carcinoma
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Nasopharyngeal Carcinoma
Lead sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Sponsor class: OTHER
First posted: 2010-12-23
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This phase II trial is studying cisplatin or nedaplatin combine with IMRT to evaluate which one is better efficacy and security in nasopharyngeal carcinoma.


Eligibility criteria: Inclusion Criteria:

Age≥18,T1-2aN1-3;T2-4NxNPC,VEGFR+,++,KPS\>70,Life expectancy≥6 months, No uncontrolled hypertension,cardiac failure,diabetes,lunacy

Exclusion Criteria:

Distant metastasis, recurrent disease

Primary outcomes:
measure: locoregionally control rate
timeFrame: 3 months
Secondary outcomes:
measure: Survival
timeFrame: 1,3,5 years
Other outcomes:
Locations:
city: Chong Qing
country: China
facility: Daping Hospital
Study officials:
References:
Clinical trial NCT02159547: IV Dexketoprofen vs Placebo in Migranie Attack
Official title: Study of Comparing Dexketoprofen to Placebo in Migraine Attack
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Migraine
Keywords: migraine, emergency department, dexketoprofen, placebo
Lead sponsor: Akdeniz University
Sponsor class: OTHER
First posted: 2014-06-10
Enrollment: 224
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: H0 hypothesis: IV dexketoprofen is equivalent to placebo in ceasing migraine attack in emergency department.

H1 hypothesis: IV dexketoprofen is not equivalent (superior) to placebo in ceasing migraine attack in emergency department.

Detailed description: Migraine attack is one of the most leading causes presentations to emergency department. Patients with migraine attack seek urgent care to cease their pain. There are so many interventions defined in the medical literature that can be used in migraine attacks. However, as a IV drug, dexketoprofen; little known whether IV dexketoprofen is superior to placebo or not. In the present study we aimed to determine the effects of IV dexketoprofen in migraine attack in emergency department.

Eligibility criteria: Inclusion Criteria:

* patients presented with headache who diagnosed as migraine attack according to the international headache society

Exclusion Criteria:

* denied to give inform concent, illiterate patients, chronic renal failure, taking NSAIDs during the last six hours, pregnancy

Primary outcomes:
measure: Visual Analogue Scale Change
timeFrame: 45 minutes
Secondary outcomes:
measure: Adverse Effects
timeFrame: 45th minutes
Other outcomes:
Locations:
city: Antalya
country: Turkey
facility: Antalya Training and Govermental Hospital
Study officials:
affiliation: Antalya Training and Govermental Hospital
name: Faruk Gungor, Pyhsician
role: PRINCIPAL_INVESTIGATOR
References:
citation: Turkcuer I, Serinken M, Eken C, Yilmaz A, Akdag O, Uyan E, Kiray C, Elicabuk H. Intravenous paracetamol versus dexketoprofen in acute migraine attack in the emergency department: a randomised clinical trial. Emerg Med J. 2014 Mar;31(3):182-5. doi: 10.1136/emermed-2013-203044. Epub 2014 Jan 6.
Clinical trial NCT06940947: Endoscopic Therapy Or Surgery for Early Colon Cancer
Official title: Endoscopic THerapy Or Surgery for Early Colon Cancer (ETHOS)
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE3
Conditions: Colon Cancer
Lead sponsor: Norwegian Department of Health and Social Affairs
Sponsor class: OTHER_GOV
Collaborators: name: Medical University of Gdansk
name: Vestre Viken Hospital Trust
name: Medical Biometry and Epidemiology_- Universitätsklinikum Hamburg Eppendorf
name: Institute of Oncology in Warsaw
name: Karolinska Institutet
name: University Hospital, Limoges
name: University Hospital, Akershus
name: University of Roma La Sapienza
name: Hospital Clinic of Barcelona
name: Leuven University Medical Center
name: University Hospital, Ghent
name: Sørlandet Hospital
name: Northern Norway Regional Health Trust
name: Helse Stavanger HF
name: Haukeland University Hospital
name: St. Olavs Hospital
name: University of Oslo
name: Frontier Science Foundation
First posted: 2025-04-23
Enrollment: 434
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The trial is a randomized head-to-head comparison of the benefits, harms and burdens of endoscopic full-thickness resection (eFTR), a novel, minimally invasive endoscopic treatment modality, for early colon cancer as compared to standard-of-care surgery.


Eligibility criteria: Inclusion Criteria:

* Newly diagnosed biopsy-confirmed colon cancer (adenocarcinoma) with macroscopic suspicion of submucosal invasion considered removable by EFTR as deemed by the local multidisciplinary team (MDT) at the participating center
* Size ≤20 mm in diameter as deemed by the colonoscopist
* No presence of histopathological high-risk features in biopsy (high grade tumor growth, budding grade 2 or 3, or lymphovascular invasion)
* Patient eligible for surgical removal as deemed by the local MDT at the participating center
* Endoscopic images or video of the tumor
* No sign of disease beyond T2N0M0 on pre-treatment imaging, biopsy sampling, and radiographic and clinical evaluation
* No contraindication for any of the two treatment arms
* Written informed consent
* No prior or synchronous CRC
* No other malignancy which is not cured
* No more than 10 adenomas or serrated polyps
* No genetic cancer syndrome (adenomatous or serrated polyposis syndrome; Lynch or Lynch-like syndrome)
* No inflammatory bowel disease

Primary outcomes:
measure: Rate of severe adverse events, re-admissions and deaths within 30 days
timeFrame: 30 days
measure: Rate of cancer recurrence or CRC death after three years
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00694447: Acupuncture for Pain and Sleep Disturbance in Knee Osteoarthritis
Official title: Exploring Outcomes and Mechanisms of Acupuncture in Treating Pain and Sleep Disturbance in Knee Osteoarthritis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sleep
Pain
Lead sponsor: Emory University
Sponsor class: OTHER
Collaborators: name: Southeast Center of Excellence in Geriatric Medicine
name: The John A. Hartford Foundation
First posted: 2008-06-10
Sex: ALL
Minimum age (years): 55
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no

Brief summary: The hypotheses of this study are: In the older population with knee OA,

* When acupoints are chosen for both sleep and pain, there are additive effects on sleep improvement and pain relief (i.e. no interaction).
* Main effects of acupuncture on sleep improvement and pain relief are anticipated when acupoints are separately targeted for sleep and for pain, respectively.


Eligibility criteria: Inclusion Criteria:

1. Patients with knee osteoarthritis, diagnosed by the ACR clinical diagnosis criteria for idiopathic OA, with at least Kellgren and Lawrence grading II and above. AND,
2. Present with knee pain at least half of the time. AND,
3. Complain of sleep disturbances associated with knee OA, with Pittsburgh Sleep Quality Index \> 5 \[36\].

Exclusion Criteria:

1. Patients with diagnosis of obstructive sleep apnea (OSA). OR,
2. Patients with dense hemiplegia secondary to cerebrovascular accident. OR,
3. NYHA Class III - patients with heart failure condition limited by minimal activity. OR,
4. Severe COPD with shortness of breath at minimal exertion. OR,
5. Peripheral vascular disease with severe claudication. OR,
6. Dementia with Mini Mental Status Exam score of 20 or less. OR,
7. Patients who received knee intra-articular corticosteroid injection within 4 weeks prior to the study or who received acupuncture treatment within 6 months. OR,
8. Unwilling to come off narcotic pain medication. OR,
9. History of bleeding diathesis or currently on anticoagulation. OR,
10. Patients currently engaged in medical legal cases related to OA or disability.

Primary outcomes:
measure: Sleep disturbances as recorded by wrist actigraph, including sleep duration and sleep efficiency. Pain as measured by 0-10 VAS and WOMAC pain scores.
timeFrame: at least 3 months
Secondary outcomes:
measure: WOMAC disability scores, IDEEA gait patterns and activity levels, medication type and amount consumed, side effects, and medical care utilization.
timeFrame: at least 3 months
Other outcomes:
Locations:
city: Atlanta
country: United States
facility: Wesley Woods Geriatric Hospital
state: Georgia
Study officials:
affiliation: Emory University
name: Wei Huang, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05484947: The HIV Testing Trends and Outcomes at a Johannesburg Trauma ICU Unit
Official title: The HIV Testing Trends and Outcomes at a Johannesburg Trauma ICU Unit
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Outcome, Fatal
Lead sponsor: University of Witwatersrand, South Africa
Sponsor class: OTHER
First posted: 2022-08-02
Enrollment: 868
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Major Trauma patients admitted to a Trauma unit at a Johannesburg Trauma Unit

Brief summary: A retrospective observational study on the HIV testing trend and outcomes in a trauma population admitted to a critical care unit for care.

Detailed description: Trauma ICU admission of 18 years and older were enrolled in the study. The HIV status was further divided into HIV-positive, HIV-negative, and HIV-unknown subgroups. The gender, ages, mechanism of injury, injuries sustained, ISS, physiological data, septic-related complications, and in-hospital mortality were noted and further analyzed.

Descriptive statistics were utilised using STATA version 15, and a p-value of \<0.05 was considered statistically significant.

Eligibility criteria: Inclusion Criteria: Trauma patients admitted to a Trauma ICU at CMJAH -

Exclusion Criteria: Those under the age of 18 or with incomplete data

-

Primary outcomes:
measure: The HIV testing trends
timeFrame: study period over two years (from 01 January 2017 till 31 December 2018)
measure: Outcomes
timeFrame: study period over two years (from 01 January 2017 till 31 December 2018)
Secondary outcomes:
measure: Mortality
timeFrame: study period over two years (from 01 January 2017 till 31 December 2018)
Other outcomes:
Locations:
city: Johannesburg
country: South Africa
facility: Charlotte Maxeke Johanneburg Academic Hospital
state: Gauteng
Study officials:
References:
Clinical trial NCT06762847: Development And Durability Of Prosthetic Liner For Transtibial Amputee
Official title: Development And Durability Of Prosthetic Liner For Transtibial Amputee
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Amputation
Lead sponsor: Superior University
Sponsor class: OTHER
First posted: 2025-01-08
Enrollment: 1
Sex: ALL
Minimum age (years): 40
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Transtibial amputee with medium stump, using the prosthetic leg for 3 years without prosthetic liners. age should be 40 years

Brief summary: About 16% of the world's population suffers from physical disabilities, of which about 65% of the population experience lower limb amputations, and in lower limb about 50% face transtibial amputation and use transtibial prosthesis. The transtibial prosthetic users face many stump-related problems.

Detailed description: As a physical interface, a prosthetic liner is commonly used as a transition material between residual limb and stiff socket to provide optimal comfort, fit, and functionality. By using a prosthetic liner, stump-related issues can be relieved, and long-term use of prosthetic devices achieved by an amputee. Prosthetic liners are so expensive due to being imported that patients can't afford them. My study aims to develop a low-cost prosthetic liner for transtibial amputees to ensure its availability and affordability for patients who need a prosthetic liner, by using material available at a local level like silicon to improve their ability to cushion and protect the residual limb from injuries induced by load-bearing normal and shear stresses. The study includes 1 sample size of 40 years of age males, Participents develop a prosthetic liner and then use it on these samples to determine liner durability and hope the results are in favor.

Eligibility criteria: Inclusion Criteria:

* Transtibial amputee with medium stump.
* Amputee which has been using the prosthetic leg for 3 years without prosthetic liners.
* Amputee with 40 years of age.

Exclusion Criteria:

* Any other amputees except transtibial.
* Amputees without using prosthetic devices.
* Amputees above 40 years of age.

Primary outcomes:
measure: Socket Comfort Score
timeFrame: 12 Months
measure: Timed Up and Go (TUG)
timeFrame: 12 months
measure: Skin Irritation Scale
timeFrame: 12 months
measure: 6-Minute Walk Test
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Peshawar
country: Pakistan
facility: PAK Rehabilitation Centre
state: Khyber Pakhtunkhwa
Study officials:
References: